Repurposed arthritis drug did not significantly improve severe COVID-19 pneumonia

A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo, according to a new study.

source https://www.sciencedaily.com/releases/2021/03/210301171018.htm